SCHEMBL387031

SCHEMBL387031

N=C(NO)C1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1842755 0.88
SCHEMBL1277640 0.88
SCHEMBL23588334 0.85 HDAC6 (0.50)
SCHEMBL13751299 0.85 HDAC6 (0.50)
SCHEMBL8256302 0.85 HDAC6 (0.50)
SCHEMBL578274 0.85 HDAC6 (0.50)
SCHEMBL6444129 0.83 NOS2 (0.54)
SCHEMBL6118244 0.81
SCHEMBL21453646 0.79
SCHEMBL596214 0.79 TP53 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111620348-B Preparation method of sodium silicate for nano silicon dioxide 安徽龙泉硅材料有限公司 2022-11-22 CN claimed
CN-111117598-B ABX based on room temperature methodnY3-nLigand regulation method and application of perovskite nano particles 华中科技大学 2021-02-09 CN claimed
CN-111620348-A Preparation method of sodium silicate for nano silicon dioxide 安徽龙泉硅材料有限公司 2020-09-04 CN claimed
CN-111117598-A ABX based on room temperature methodnY3-nLigand regulation method and application of perovskite nano particles 华中科技大学 2020-05-08 CN claimed
CN-122036605-A Antagonists of GPR39 proteins 俄勒冈健康科学大学 2026-05-15 CN disclosed
US-20260132147-A1 BAX INHIBITORS AND USES THEREOF CASE WESTERN RESERVE UNIV (US) 2026-05-14 US disclosed
EP-4719369-A2 INHIBITORS OF FATTY ACID BINDING PROTEINS (FABPS), METHODS OF USE AND METHODS OF MAKING Celloram, Inc. (US) 2026-04-08 EP disclosed
US-12479857-B2 Bax inhibitors and uses thereof CASE WESTERN RESERVE UNIVERSITY (US) 2025-11-25 US disclosed
US-20250340528-A1 TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS AG (CH) 2025-11-06 US disclosed
US-12459920-B2 Targeted protein degradation MONTE ROSA THERAPEUTICS AG (CH) 2025-11-04 US disclosed
EP-4021901-B1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2025-09-24 EP disclosed
US-20250243180-A1 TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS AG (CH) 2025-07-31 US disclosed
WO-2002094795-A1 4-AMINOPYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-11-28 WO disclosed
US-20020128263-A1 Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles F.HOFFMANN-LA ROCHE AG (CH) 2002-09-12 US disclosed
EP-1056759-B1 2-(PURIN-9-YL) -TETRAHYDROFURAN-3, 4-DIOL DERIVATIVES GLAXO GROUP LTD (GB) 2002-09-04 EP disclosed
WO-2002046166-A1 PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2002-06-13 WO disclosed
US-20020019424-A1 1-sulfonyl pyrrolidine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2002-02-14 US disclosed
WO-2002002554-A1 SULFONYL-PYRROLIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2002-01-10 WO disclosed
US-5643929-A TREATMENT OF PICORNAVIRAL OR RHINOVIRUS AND CHEMICAL INTERMEDIATES SANOFI WINTHROP, INC. (US) 1997-07-01 US disclosed
US-5464848-A 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents STERLING WINTHROP INC. (US) 1995-11-07 US disclosed